AI Revolution Ignites Top 5 Stocks for 2023: Download Free Report

Date:

Altimmune Inc (NASDAQ: ALT) is one of the top five AI stocks to consider for 2023, as the global AI boom is predicted to reach over $1.81 trillion by 2030, according to Grand View Research. Altimmune, a healthcare sector company, has experienced a decline in annual sales by 30.84% over the past five years. However, its average yearly earnings per share have been noted at a positive 15.26%.

Altimmune has a float of $53.19 million and has outstanding shares totaling $53.73 million. Despite the slip in sales, the company has shown resilience with 52 employees.

When evaluating the stock, it’s important to consider investor sentiment. Altimmune has an insider ownership of 1.01% and institutional ownership of 65.84%. Recent insider transactions include a director purchasing 300 shares at a rate of $2.88, bringing their total ownership to 29,785 shares. Additionally, the company’s CFO bought 10,000 shares for $4.31, resulting in a transaction worth $43,140 and bringing their total ownership to 22,010 shares.

For the last quarter, Altimmune posted earnings per share (EPS) of -$0.39, surpassing the estimated -$0.42 by $0.03. The company also achieved a return on equity of -44.07%. Wall Street analysts predict a further improvement, forecasting earnings of -0.46 per share for the current fiscal year and 15.26% per share for the next fiscal year.

Altimmune’s performance indicators reveal a quick ratio of 12.89 for the past quarter and a price to sales ratio of 468.22 for the trailing twelve months. The company’s diluted EPS for the trailing twelve months stands at -1.54, with predictions of -0.42 for the next quarter and -1.82 in one year’s time.

See also  Palantir Stock Surges 167% in 2023, Analyst Predicts 40% Increase

Altimmune saw its 5-day average volume at 1.41 million, a decrease from its year-to-date volume of 1.62 million. The stock’s Stochastic %D was 26.13% in the previous 9 days, indicating a slightly bearish trend. Additionally, Altimmune showed a historical volatility of 59.52% in the past 14 days, lower than the 62.39% volatility in the past 100 days.

Currently, Altimmune’s 50-day Moving Average is $2.55, while its 200-day Moving Average is $5.04. The stock faces resistance levels at $2.52, $2.60, and $2.71, with $2.34 and $2.23 as support levels.

With 53,729K shares outstanding and a market cap of $131.10 million, Altimmune’s sales have totaled -70K annually with an income of -84,710K. Last quarter, the company’s sales reached 10K, while income amounted to -16,060K.

Considering Altimmune’s potential in the AI industry and its financial performance, it could be a stock worth considering for investors looking to capitalize on the AI revolution.

Frequently Asked Questions (FAQs) Related to the Above News

What is Altimmune Inc?

Altimmune Inc is a healthcare sector company that is poised to benefit from the artificial intelligence revolution.

How is Altimmune Inc positioned in the AI market?

Altimmune Inc is well-positioned to capitalize on the AI market, which is expected to reach $1.81 trillion by 2030. The company offers a promising investment opportunity for those looking to profit from this emerging trend.

How has Altimmune Inc performed in recent years?

Altimmune Inc has shown resilience, with an average yearly earnings per share increase of 15.26%. While the company experienced a dip in annual sales over the past five years, its recent performance indicators are encouraging.

What is the ownership structure of Altimmune Inc?

Altimmune Inc has a float of $53.19 million and outstanding shares reaching $53.73 million. Insider ownership stands at 1.01%, and institutional ownership is at 65.84%.

What is the financial performance of Altimmune Inc?

Altimmune Inc outperformed expectations in the last quarter, beating predicted earnings per share by $0.03. Wall Street analysts anticipate earnings of -$0.46 per share for the current fiscal year.

What are analysts' predictions for Altimmune Inc's future earnings?

Analysts predict an earnings increase of 15.26% per share for the next fiscal year, highlighting Altimmune Inc's growth potential in the AI industry.

What are some key performance indicators for Altimmune Inc?

Altimmune Inc's quick ratio for the past quarter was 12.89, indicating its robust liquidity position. The stock's price-to-sales ratio for the trailing twelve months is 468.22.

How has Altimmune Inc's stock volume and volatility been?

Altimmune Inc's stock volume has shown a negative change in recent times. It exhibited a historical volatility of 59.52% in the past 14 days, lower than its 100-day volatility of 62.39%.

What are the support and resistance levels for Altimmune Inc's stock?

Altimmune Inc's stock faces resistance levels at $2.52, $2.60, and $2.71, while support levels are at $2.34, $2.23, and $2.15.

What is the market cap and annual sales of Altimmune Inc?

Altimmune Inc currently has a market cap of $131.10 million and annual sales total -70K based on its annual income of -84,710K.

Is Altimmune Inc a good investment opportunity?

Altimmune Inc represents a compelling investment opportunity in the AI industry, given its innovative approach and positive performance indicators. However, investors should conduct their own research and exercise caution when making investment decisions.

Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.

Share post:

Subscribe

Popular

More like this
Related

Obama’s Techno-Optimism Shifts as Democrats Navigate Changing Tech Landscape

Explore the evolution of tech policy from Obama's optimism to Harris's vision at the Democratic National Convention. What's next for Democrats in tech?

Tech Evolution: From Obama’s Optimism to Harris’s Vision

Explore the evolution of tech policy from Obama's optimism to Harris's vision at the Democratic National Convention. What's next for Democrats in tech?

Tonix Pharmaceuticals TNXP Shares Fall 14.61% After Q2 Earnings Report

Tonix Pharmaceuticals TNXP shares decline 14.61% post-Q2 earnings report. Evaluate investment strategy based on company updates and market dynamics.

The Future of Good Jobs: Why College Degrees are Essential through 2031

Discover the future of good jobs through 2031 and why college degrees are essential. Learn more about job projections and AI's influence.